Ampio provides update on results from pre-ind enabling studies

Englewood, colo. , feb. 14, 2024 /prnewswire/ -- ampio pharmaceuticals, inc. (nyse american: ampe) (the "company" or "ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its oa-201 program, today announced the efficacy results from recently completed nonclinical pre-ind enabling studies with oa-201, ampio's only product development opportunity.
AMPE Ratings Summary
AMPE Quant Ranking